An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma

Trial Profile

An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2018

At a glance

  • Drugs Daratumumab (Primary) ; Bortezomib; Carfilzomib; Dexamethasone; Dexamethasone; Lenalidomide; Melphalan; Pomalidomide; Prednisone; Prednisone; Thalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational
  • Acronyms EQUULEUS
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Dec 2017 Results (n=22) assessing the safety profile and efficacy of Daratumumab in combination with KRd in patients with newly diagnosed multiple myeloma, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results (n=85) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results (n=103) assessing daratumumab in combination with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma (RRMM) patients with ≥2 prior lines of therapy, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top